Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PHVS, CBAY, ACRS, KURA, KNTE, and represent 85.77% of Foresite Capital Management IV's stock portfolio.
  • Reduced shares in these 1 stock: LYEL.
  • Foresite Capital Management IV was a net seller of stock by $-1.3M.
  • Foresite Capital Management IV has $180M in assets under management (AUM), dropping by -11.49%.
  • Central Index Key (CIK): 0001704132

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Foresite Capital Management IV holds 7 positions in its portfolio as reported in the September 2023 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pharvaris N V (PHVS) 43.4 $78M 3.7M 20.87
 View chart
Cymabay Therapeutics (CBAY) 14.8 $27M 1.8M 14.91
 View chart
Aclaris Therapeutics (ACRS) 10.7 $19M 2.8M 6.85
 View chart
Kura Oncology (KURA) 9.4 $17M 1.8M 9.12
 View chart
Kinnate Biopharma (KNTE) 7.5 $14M 9.7M 1.40
 View chart
Lyell Immunopharma (LYEL) 7.2 $13M -9% 8.8M 1.47
 View chart
Syndax Pharmaceuticals (SNDX) 7.1 $13M 875k 14.52
 View chart

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017

View all past filings